Business drug withdrawal

Ipsen Withdraws Tazverik Due to Safety Concerns

Analysis based on 14 articles · First reported Mar 09, 2026 · Last updated Mar 09, 2026

Sentiment

-30

Attention

Articles

Market Impact

Direct

Live prominence charts, article sentiment distribution, and event development timeline available on the NewsDesk Dashboard

Market Impact

The withdrawal of Tazemetostat by Ipsen is a negative event for the pharmaceutical market, particularly for patients relying on the drug for follicular lymphoma and epithelioid sarcoma. While Ipsen states no impact on financial guidance, its stock experienced a decline, reflecting investor concern over the product's failure.

Pharmaceuticals Biotechnology

Event Summary

Ipsen has announced the voluntary withdrawal of its drug Tazverik (tazemetostat) from all markets due to emerging safety data from the Phase Ib/III SYMPHONY-1 trial. An Independent Data Monitoring Committee advised that the risks of secondary hematologic malignancies may outweigh the potential benefits for patients. This withdrawal affects Tazverik's indications for follicular lymphoma and epithelioid sarcoma. Ipsen is discontinuing all related clinical trials and expanded access programs and is collaborating with the United States===Food and Drug Administration on the withdrawal process. Despite the setback, Ipsen does not expect this to impact its financial guidance.

Key Actions

100 Ipsen voluntarily withdrew drug Tazemetostat from all markets

80 Ipsen initiated steps to stop treatment with Tazemetostat for all patients

70 Ipsen discontinued all active Tazemetostat clinical trials and expanded access programs

50 Ipsen working with United States===Food and Drug Administration on withdrawal execution United States===Food and Drug Administration

Entities Involved

stock

Ipsen

Ipsen is voluntarily withdrawing its drug Tazverik from all markets due to safety concerns identified in the SYMPHONY-1 trial. This decision, while disappointing, is not expected to impact Ipsen's financial guidance. Ipsen's stock price declined by 5.57% on the Frankfurt Stock Exchange following the announcement.

Importance 100 Sentiment -40

govactor

United States===Food and Drug Administration

The United States===Food and Drug Administration had previously granted accelerated approval for Tazverik in 2020. Ipsen is now working with the United States===Food and Drug Administration on the necessary steps to execute the withdrawal of Tazverik.

Importance 60 Sentiment 0

per

Christelle Huguet

Christelle Huguet, EVP Head of R&D at Ipsen, expressed disappointment regarding the withdrawal but emphasized patient safety as a priority.

Importance 20 Sentiment 0

Relationships

Christelle Huguet related ↔ Ipsen

NEWSDESK

Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard